Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Biomed Pharmacother. 2021 Sep 21;143:112172. doi: 10.1016/j.biopha.2021.112172

Figure 8.

Figure 8.

Treprostinil improves hepatic mitochondrial dynamics after renal IRI. Hepatic mRNA expressions of (A) Mfn1 and (B) Mfn2 at 24-hours post-reperfusion measured by qPCR, normalized to 18S and expressed as fold-change over sham. Hepatic protein expression of (C) Drp-1 and (D) Sirt3 at 3- and 6-hours post-reperfusion, respectively measured by western blot, normalized to Cox-IV and quantified using Image J software. Data represented are mean ± SEM. *P<0.05, **P<0.01 vs. sham; ϕϕP<0.01 vs. IRI-placebo (n = 4–5/group). One-way ANOVA, Tukey’s multiple comparisons test. Mfn1: Mitofusin-1; Mfn2: Mitofusin-2; Drp-1: Dynamin-related protein 1; Sirt3: NAD-dependent deacetylase sirtuin-3; Cox-IV: Cytochrome c oxidase subunit 4; PLB: IRI-placebo; TRE: IRI-treprostinil.